Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prevention of Chemotherapy Induced Cardiotoxicity in Children With Bone Tumors and Acute Myeloid Leukemia
NCT03389724Phase 3Completed
- Sponsor
- Children's Cancer Hospital Egypt 57357
- Start
- Nov 2017
- Primary completion
- Nov 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of captopril in Cardiotoxicity (2 arms), sponsored by Children's Cancer Hospital Egypt 57357. Primary endpoints: Effect of ACE-I in preventing chemotherapy-related cardiotoxicity at 3 years, Role of Troponin I (TnI) as an early marker of cardiac toxicity at 3 years and 1 more. Started Nov 2017; status: completed.
02
Drugs
captopril
03
Conditions
Cardiotoxicity
Beyond the preview
Go deeper on NCT03389724.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03389724.